[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-and-cardiovascular-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-and-cardiovascular-risk":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652918","obesial-a-prospective-interventional-real-world-study-of-a-multidisciplinary-obesity-management-programme-100652918",false,"NCT07779343","OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","OBESIAL","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* BMI ≥30 kg\u002Fm²\n* Written informed consent obtained prior to enrolment\n\nExclusion Criteria:\n\n* Refusal to participate or inability to adhere to follow-up procedures\n* Pregnancy at enrolment\n* Severe or unstable comorbidities compromising safety or participation, including:\n\n  * Recent acute cardiovascular event (\\\u003C60 days)\n  * Active malignancy\n  * Severe unstable organic disease\n* Previous bariatric surgery\n* Obesity pharmacotherapy within the previous 90 days\n* Known contraindication to planned therapeutic options\n* Severe unstable psychiatric disorders\n* Genetic obesity or obesity secondary to uncontrolled endocrine disease\n\nExclusion Criteria During Follow-up\n\n* Pregnancy occurring during follow-up\n* Initiation of chronic treatment associated with weight gain","ALL","18 Years","65 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.",[27,28,29,30],"Obesity Difficult Airway Airway Management","Obesity Adult Onset","Obesity and Cardiovascular Risk","Obesity Type 2 Diabetes Mellitus",[32,33,34,35,36],"obesity","adult obesity","multidisciplinary care","lifestyle interventions","GLP-1 receptor agonists","RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-01-22",{"date":45,"type":21},"2028-01-23",{"name":47,"class":48},"University of Health Sciences, Algeria","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100641062","phase-2-a-phase-2-study-to-evaluate-the-pharmacodynamics-safety-and-tolerability-of-bge-102-in-participants-with-obesity-and-cardiovascular-risk-factors-100641062","NCT07656727","A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","Key Inclusion Criteria:\n\n* Obese Male and Female adults with BMI 32-42 kg\u002Fm²\n* Elevated blood test for hsCRP consistent with chronic systemic inflammation\n* At least one cardiovascular risk factor or metabolic syndrome feature\n* Stable background therapies and willing to maintain stable diet\u002Fexercise habits during the study\n\nKey Exclusion Criteria:\n\n* Type 1 diabetes,\n* Uncontrolled Type 2 diabetes,\n* Uncontrolled hypertension and \u002For hyperlipidemia\n* Recent weight change of 5% or more,\n* Use of weight-loss medications\u002Fprograms\n* Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.\n* Clinically significant ECG abnormalities or arrhythmias\n* Use of prohibited medications (including GLP-1 therapies, immunosuppressants, chronic anti-inflammatory drugs, or moderate or strong CYP3A4 modulators)\n* Contraindications to MRI\n* Clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \\[bariatric\\] surgery or restrictive bariatric surgery), or have an endoscopic and\u002For device-based therapy for obesity\n* Women who are pregnant or nursing",{"count":58,"type":21},160,[60],"PHASE2","The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.",[29],[64,65,66,67,68,69],"Obesity","Cardiovascular","BGE-102","hsCRP","BioAge","NLRP3","2026-06-15",{"date":72,"type":41},"2026-06-18",{"date":74,"type":41},"2026-06-11",{"date":76,"type":21},"2026-12",{"name":78,"class":79},"BioAge Labs, Inc.","INDUSTRY",13,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100615798","phase-3-effect-of-metformin-use-on-weight-loss-in-obese-non-diabetic-people-mowri-100615798","NCT07297290","Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)","Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People","MOWRI","Inclusion Criteria:\n\n* • Obesity (defined as body mass index ≥ 30kg\u002Fm2),\n\n  * Fasting plasma glucose (\\\u003C7.0mmol\u002FL)\n  * No medical treatment for weight control in the previous 12 months\n  * No participation in a current clinical trial\n\nExclusion Criteria:\n\n* • Obesity (defined as body mass index ≥ 30kg\u002Fm2),\n\n  * Fasting plasma glucose (\\\u003C7.0mmol\u002FL)\n  * No medical treatment for weight control in the previous 12 months\n  * No participation in a current clinical trial","20 Years","59 Years",{"count":92,"type":21},220,[94],"PHASE3","Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.\n\nMetformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.",[29,97,98],"Insulin Resistance","Obesity (Body Mass Index >30 kg\u002Fm2)",[64,100,101,102],"Metformin use","Weight loss","Non-diabetic","2025-12-08",{"date":105,"type":41},"2025-12-22",{"date":107,"type":41},"2025-07-23",{"date":109,"type":21},"2027-09-30",{"name":111,"class":112},"University Of Nigeria Teaching Hospital","NETWORK",2]